Cargando…
CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene
Exon skipping is a promising strategy for Duchenne muscular dystrophy (DMD) disease-modifying therapy. To make this approach safe, ensuring that excluding one or more exons will restore the reading frame and that the resulting protein will retain critical functions of the full-length dystrophin prot...
Autores principales: | Egorova, Tatiana V., Zotova, Evgenia D., Reshetov, Denis A., Polikarpova, Anna V., Vassilieva, Svetlana G., Vlodavets, Dmitry V., Gavrilov, Alexey A., Ulianov, Sergey V., Buchman, Vladimir L., Deykin, Alexei V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505476/ https://www.ncbi.nlm.nih.gov/pubmed/31028078 http://dx.doi.org/10.1242/dmm.037655 |
Ejemplares similares
-
CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein
por: Egorova, Tatiana V., et al.
Publicado: (2023) -
Symptomatic therapy of Duchenne Muscular
Dystrophy (DMD)
por: Rüdel, Reinhardt
Publicado: (2012) -
Vascular therapy for Duchenne muscular dystrophy (DMD)
por: Thapa, Sangharsha, et al.
Publicado: (2023) -
In-Frame Deletion of Dystrophin Exons 8–50 Results in DMD Phenotype
por: Egorova, Tatiana V., et al.
Publicado: (2023) -
Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy
por: Gartz, Melanie, et al.
Publicado: (2020)